High-Specific-Activity-I-131-Mibg Versus Lu-177-Dotatate Targeted Radionuclide Therapy For Metastatic Pheochromocytoma And Paraganglioma

Targeted radionuclide therapies (TRT) using I-131-metaiodobenzylguanidine (I-131-MIBG) and peptide receptor radionuclide therapy (Lu-177 or Y-90) represent several of the therapeutic options in the management of metastatic/inoperable pheochromocytoma/paraganglioma. Recently, high-specific-activity-I-131-MIBGtherapy was approved by the FDA and both Lu-177-DOTATATE and I-131-MIBG therapy were recommended by the National Comprehensive Cancer Network guidelines for the treatment of metastatic pheochromocytoma/paraganglioma. However, a clinical dilemmaoften arises in the selection of TRT, especially when a patient can be treated with either type of therapy based on eligibility by MIBG and somatostatin receptor imaging. To address this problem, we assembled a group of international experts, including oncologists, endocrinologists, and nuclear medicine physicians, with substantial experience in treating neuroendocrine tumors with TRTs to develop consensus and provide expert recommendations and perspectives on how to select between these two therapeutic options for metastatic/inoperable pheochromocytoma/paraganglioma. This article aims to summarize the survival outcomes of the available TRTs; discuss personalized treatment strategies based on functional imaging scans; address practical issues, including regulatory approvals; and compare toxicities and risk factors across treatments. Furthermore, it discusses the emerging TRTs.